Progression-free survival with PI3Kδ inhibitor INCB040093 alone or in combination with JAK1 inhibitor itacitinib, by lymphoma subtype (ITT)
| Tumor subtype . | Monotherapy (n = 49) . | Combination therapy (n = 72) . | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of patients in disease subgroup, n . | Events, n . | Median PFS (95% CI), mo . | PFS rate at 12 mo (95% CI), % . | No. of patients in disease subgroup, n . | Events, N . | Median PFS (95% CI), mo . | PFS rate at 12 mo (95% CI), % . | |
| NHL | ||||||||
| Indolent | ||||||||
| FL | 8 | 5 | 5.7 (1.7-NE) | 29 (4-61) | 11 | 7 | 6.7 (2.4-NE) | 35 (9-64) |
| WM | 1 | 0 | NR (NE-NE) | 100 (NE-NE) | 2 | 0 | NR (NE-NE) | 100 (NE-NE) |
| Nodal MZL | 1 | 0 | NR (NE-NE) | NR (NE-NE) | 1 | 0 | NR (NE-NE) | 100 (NE-NE) |
| Splenic MZL | 1 | 0 | NR (NE-NE) | NR (NE-NE) | 2 | 2 | 4.8 (0.7-8.9) | 0 (NE-NE) |
| Aggressive | ||||||||
| DLBCL | 2 | 1 | NR (2.1-NE) | 50 (1-91) | 23 | 13 | 2.2 (0.7-6.6) | NE (NE-NE) |
| MCL | 6 | 4 | 12.5 (1.6-20.1) | 50 (11-80) | 0 | — | — | — |
| Transformed NHL | 1 | 0 | NR (NE-NE) | NR (NE-NE) | 8 | 7 | 1.5 (0.1-2.6) | NE (NE-NE) |
| CLL/SLL | 12 | 6 | 16.7 (3.9-NE) | 55 (19-81) | 1 | 1 | 5.4 (NE-NE) | 0 (NE-NE) |
| cHL | 17 | 12 | 8.3 (2.1-11.6) | 8 (1-31) | 21 | 10 | 23.1 (4.0-NE) | 51 (27-71) |
| NLP HL | 0 | — | — | — | 1 | 1 | 8.5 (NE-NE) | 0 (NE-NE) |
| PMBCL | 0 | — | — | — | 2 | 2 | 2.1 (0.7-3.4) | 0 (NE-NE) |
| Tumor subtype . | Monotherapy (n = 49) . | Combination therapy (n = 72) . | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of patients in disease subgroup, n . | Events, n . | Median PFS (95% CI), mo . | PFS rate at 12 mo (95% CI), % . | No. of patients in disease subgroup, n . | Events, N . | Median PFS (95% CI), mo . | PFS rate at 12 mo (95% CI), % . | |
| NHL | ||||||||
| Indolent | ||||||||
| FL | 8 | 5 | 5.7 (1.7-NE) | 29 (4-61) | 11 | 7 | 6.7 (2.4-NE) | 35 (9-64) |
| WM | 1 | 0 | NR (NE-NE) | 100 (NE-NE) | 2 | 0 | NR (NE-NE) | 100 (NE-NE) |
| Nodal MZL | 1 | 0 | NR (NE-NE) | NR (NE-NE) | 1 | 0 | NR (NE-NE) | 100 (NE-NE) |
| Splenic MZL | 1 | 0 | NR (NE-NE) | NR (NE-NE) | 2 | 2 | 4.8 (0.7-8.9) | 0 (NE-NE) |
| Aggressive | ||||||||
| DLBCL | 2 | 1 | NR (2.1-NE) | 50 (1-91) | 23 | 13 | 2.2 (0.7-6.6) | NE (NE-NE) |
| MCL | 6 | 4 | 12.5 (1.6-20.1) | 50 (11-80) | 0 | — | — | — |
| Transformed NHL | 1 | 0 | NR (NE-NE) | NR (NE-NE) | 8 | 7 | 1.5 (0.1-2.6) | NE (NE-NE) |
| CLL/SLL | 12 | 6 | 16.7 (3.9-NE) | 55 (19-81) | 1 | 1 | 5.4 (NE-NE) | 0 (NE-NE) |
| cHL | 17 | 12 | 8.3 (2.1-11.6) | 8 (1-31) | 21 | 10 | 23.1 (4.0-NE) | 51 (27-71) |
| NLP HL | 0 | — | — | — | 1 | 1 | 8.5 (NE-NE) | 0 (NE-NE) |
| PMBCL | 0 | — | — | — | 2 | 2 | 2.1 (0.7-3.4) | 0 (NE-NE) |